

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”) hereby announces that, on December 13, 2022, Ms. Li Quan has tendered her resignation as a non-executive Director and a member of the audit committee of the Board (the “**Audit Committee**”) with effect from December 19, 2022 due to personal work arrangement.

Ms. Li Quan has confirmed that she has no disagreement with the Board, nor is there any matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company is in the process of identifying and appointing suitable candidate to fill the vacancy of the Audit Committee upon Ms. Li Quan’s resignation becoming effective to comply with the relevant requirements pursuant to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and will make further announcement(s) as and when appropriate in accordance with the Listing Rules.

The Board would like to take this opportunity to express its gratitude to Ms. Li Quan for her contribution and service to the Company during her tenure of office.

By order of the Board

SciClone Pharmaceuticals (Holdings) Limited

ZHAO Hong

Executive Director, Chief Executive Officer and President

Hong Kong, December 13, 2022

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*